Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma

Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma

The development of immune checkpoint inhibitors (ICI) has dramatically changed the landscape of therapies for metastatic renal cell carcinoma. However, many patients do not benefit from such therapy and prognostic or predictive validated biomarker validated for ICI are still needed to better select...

Full description

Bibliographic Details
Main Authors: Emilien Billon, Brice Chanez, Philippe Rochigneux, Laurence Albiges, Cécile Vicier, Géraldine Pignot, Jochen Walz, Anne-Sophie Chretien, Gwenaelle Gravis, Daniel Olive
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Immunology
Subjects:
renal cell carcinoma
butyrophilin
nivolumab
immunotherapy
γδ T cells
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.670827/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.670827/full

Similar Items